Trending...
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis
PHILADELPHIA - OhioPen -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approval to conduct a clinical trial (officially referred to as an IND) for the treatment of "the appearance of the structure of skin with plaques due to psoriasis." SFA plans to expand the evaluation of one of its five microbiome-derived drugs, SFA002, in this new trial.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on Ohio Pen
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on Ohio Pen
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
More on Ohio Pen
- World-Class, Turnkey Cro Facility Available Through Bankruptcy Sale with Full Suite of Lab Equipment & Intellectual Property
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at jameskirwin@sfatherapeutics.com for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on Ohio Pen
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- Rx Processing Corp.com The Forth Of July 2025
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
Source: SFA Therapeutics, Inc.
0 Comments
Latest on Ohio Pen
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Champions Group Expands Midwest Presence with Acquisition of McAfee Heating and Air Conditioning
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- "Drink Like It's 1776… Just Kidding, It's 1932." A Golden Age Patriotic Pop-Up
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Nationwide Completes Acquisition of Allstate Employer Stop Loss Business for $1.25 billion
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT